LSTA · Lisata Therapeutics, Inc. · Executive Compensation
$1.68
-0.22 (-11.58%)
At close · Sep 10
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and existing capital resources, management has concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of twelve months from the date of issuance of the accompanying consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$17.12M
Shares
9.01M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| David Mazzo | President and Chief Executive Officer | $1,691,174 |
| Kristen Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $1,065,061 |
| James Nisco | Senior Vice President, Finance and Treasury and Chief Accounting Officer | $516,166 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David Mazzo | President and Chief Executive Officer | $1,408,382 |
| David Slack | Former President and Chief Business Officer | $1,213,429 |
| Kristen Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $969,817 |
| James Nisco | Senior Vice President, Finance and Treasury and Chief Accounting Officer | $438,554 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David Mazzo | President and Chief Executive Officer | $1,929,933 |
| Kristen Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $1,124,102 |
| David Slack | Former President and Chief Business Officer | $316,176 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kristen Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $1,858,333 |
| David Mazzo | Chief Executive Officer | $1,335,216 |
| David Slack | Former President and Chief Business Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David Mazzo | President and Chief Executive Officer | $1,435,031 |
| Douglas Losordo | Former Chief Medical Officer | $712,890 |
| Todd C. Girolamo | General Counsel and Corporate Secretary | $655,197 |
| Joseph Talamo | Former Chief Financial Officer | $495,138 |
| William K. Sietsema | Vice President, Global Regulatory Affairs | $400,177 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| David Mazzo | President and Chief Executive Officer | $1,539,651 |
| Douglas Losordo | Former Chief Medical Officer | $890,011 |
| Joseph Talamo | Former Chief Financial Officer | $676,630 |
| Todd C. Girolamo | General Counsel and Corporate Secretary | $657,661 |
| William K. Sietsema | Vice President, Global Regulatory Affairs | $390,181 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| David Mazzo | President and Chief Executive Officer | $1,892,242 |
| Douglas Losordo | Chief Medical Officer | $1,012,429 |
| Joseph Talamo | Chief Financial Officer | $834,955 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Kristen K. Buck, M.D. | Executive Vice President of R&D and Chief Medical Officer | Terminated | 2026-08-04 |
Key facts
CIK
320017
CUSIP
128058302
13F (30d)
22 filings
22 filers
Visit website
Investor relations